Candel Therapeutics (CADL) Operating Leases (2022 - 2025)

Candel Therapeutics (CADL) has 4 years of Operating Leases data on file, last reported at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases rose 258.48% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 258.48% YoY), and the FY2025 full-year result was $1.5 million, up 258.48% from the prior year.
• Operating Leases fell to $1.5 million in Q4 2025, from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.8 million in Q1 2022 to a low of $104000.0 in Q2 2025.
• A 4-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Operating Leases.
• Peak annual rise in Operating Leases reached 258.48% in 2025, while the deepest fall reached 85.1% in 2025.
• Tracing CADL's Operating Leases over 4 years: stood at $1.5 million in 2022, then slumped by 34.52% to $973000.0 in 2023, then sank by 58.17% to $407000.0 in 2024, then jumped by 258.48% to $1.5 million in 2025.
• Business Quant data shows CADL's Operating Leases at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $104000.0 in Q2 2025.